Dickson R, Awasthi S, Demellweek C, Williamson P
University of Liverpool, Liverpool Reviews and Implementation Group, 2nd Floor, Sherrington Building, Liverpool, Merseyside, UK, L69 3GE.
Cochrane Database Syst Rev. 2007 Jul 18(2):CD000371. doi: 10.1002/14651858.CD000371.pub2.
In communities where helminth (worm) infections are common, they may contribute to poor nutritional status, anaemia, and impaired growth and learning in children. The World Health Organization, the World Bank and others recommend that children are routinely given deworming drugs in developing countries. This requires resources to deliver.
To summarise the effects of anthelmintic drug treatment in children in relation to their growth and cognitive performance.
We searched the Cochrane Infectious Diseases Group Specialized Register (August 2004), CENTRAL) The Cochrane Library Issue 3, 2004), MEDLINE (1966 to August 2004), EMBASE (1980 to August 2004), and LILACS (August 2004). We contacted experts in the field.
Randomised and quasi-randomised trials of drug treatment compared with placebo or no drug treatment for intestinal helminths in children.
Trial quality was assessed and data were extracted independently by two reviewers. Study authors were contacted for additional information.
Thirty trials involving more than 1500 children were included. There was potential for bias from inadequate concealment of allocation. Studies varied in relation to target groups, drugs administered and treatment regimens. Compared to placebo or no drug treatment, drug treatment for helminths was associated with some positive effects on change in weight, height and skinfold thickness. However there was significant heterogeneity between the results of the trials. There were some positive effects on mean weight change in the trials reporting this outcome; after a single dose (any anthelminth) the pooled estimate was 0.17 kg, (95% CI 0.10 to 0.25; fixed effects model assumed); and 0.38 kg (95% CI 0.00 to 0.77; random effects model assumed). Results from trials giving multiple doses showed mean weight change under one year of follow up of 0.10 kg (95% CI 0.04 to 0.17; fixed effects assumed); or 0.15 (95% CI 0.00 to 0.30; random effects assumed). At more than one year of follow up, mean weight change was 0.12 kg (95% CI -0.02 to 0.26; fixed effects assumed) and 0.43 (95% CI -0.61 to 1.47; random effects model assumed). Results from studies of cognitive performance were mixed and inconclusive.
AUTHORS' CONCLUSIONS: There is some limited evidence that routine treatment of children in areas where helminths are common has small effects on weight gain, but this is not consistent between trials. There is insufficient evidence to know whether this intervention improves cognitive performance. Our interpretation of these results is that the current public health programme investments in this intervention, based on the expectation that there will be an improvement in growth and learning, are not based on consistent or reliable evidence.
在蠕虫感染常见的社区,蠕虫感染可能导致儿童营养状况不佳、贫血以及生长发育和学习能力受损。世界卫生组织、世界银行及其他机构建议,在发展中国家应定期给儿童服用驱虫药。这需要投入资源来实施。
总结驱虫药物治疗对儿童生长和认知能力的影响。
我们检索了Cochrane传染病学组专业注册库(2004年8月)、Cochrane中心对照试验注册库(CENTRAL,《Cochrane图书馆》2004年第3期)、MEDLINE(1966年至2004年8月)、EMBASE(1980年至2004年8月)以及LILACS(2004年8月)。我们还联系了该领域的专家。
比较药物治疗与安慰剂或不进行药物治疗对儿童肠道蠕虫感染疗效的随机和半随机试验。
由两名评价员独立评估试验质量并提取数据。与研究作者联系以获取更多信息。
纳入了30项涉及1500多名儿童的试验。存在分配方案隐匿不足导致的偏倚可能性。各项研究在目标群体、所用药物和治疗方案方面存在差异。与安慰剂或不进行药物治疗相比,蠕虫感染的药物治疗对体重、身高和皮褶厚度的变化有一些积极影响。然而,试验结果之间存在显著异质性。报告该结果的试验对平均体重变化有一些积极影响;单次给药(任何驱虫药)后,合并估计值为0.17千克(95%可信区间0.10至0.25;假定为固定效应模型);0.38千克(95%可信区间0.00至0.77;假定为随机效应模型)。多次给药试验的结果显示,随访一年以下的平均体重变化为0.10千克(95%可信区间0.04至0.17;假定为固定效应);或0.15(95%可信区间0.00至0.30;假定为随机效应)。随访一年以上,平均体重变化为0.12千克(95%可信区间-0.02至0.26;假定为固定效应)和0.43(95%可信区间-0.61至1.47;随机效应模型)。关于认知能力的研究结果不一,尚无定论。
有一些有限的证据表明,在蠕虫感染常见地区对儿童进行常规治疗对体重增加有微小影响,但各试验结果并不一致。没有足够的证据表明这种干预措施能改善认知能力。我们对这些结果的解读是,当前基于预期生长发育和学习能力会得到改善而对该干预措施进行的公共卫生项目投资并非基于一致或可靠的证据。